Recommendation of the President – Imfinzi (durvalumab) + Imjudo (tremelimumab)
On 1 October 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 105/2024 on the evaluation of the drug combination Imfinzi (durvalumab) + Imjudo (tremelimumab) under the drug program “Treatment of patients with lung cancer (ICD-10 C34) and pleural mesothelioma (ICD-10 C45)”